Newsroom

Download PDF AV-412 Has Potential to Address Drug Resistance in Non-Small Cell Lung and Breast Cancer CAMBRIDGE, MA, November 13, 2007 – AVEO Pharmaceuticals, Inc., today announced encouraging preclinical data that show the potential of AV-412, a novel next generation oral tyrosine kinase inhibitor, as a therapeutic agent for the treatment of drug-resistant cancers expressing

Download PDF Company Initiates Phase 2 Clinical Trial of AV-951 in Patients with RCC Cambridge, MA, November 6, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced positive results from an expanded Phase 1 clinical trial of its lead product

Download PDF CAMBRIDGE, MA, November 1, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of David Johnston to the newly created position of Chief Financial Officer.  “As we continue to expand our pipeline of targeted cancer therapies,

Download PDF CAMBRIDGE, MA, October 30, 2007 – AVEO Pharmaceuticals, Inc., today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 9:50 a.m. ET at The New York Palace Hotel in New York

Download PDF October 2, 2007, Sydney, Australia and Cambridge, MA –   Peptech Limited (ASX: PTD) and AVEO Pharmaceuticals Inc. today announced they have entered into a non-exclusive research and commercialisation agreement in which AVEO will access Peptech’s SuperhumanisationTM technology to humanise internally-derived drug candidates.  The Superhumanisation™ technology allows for modifying antibodies generated in animals so

Download PDF CAMBRIDGE, MA, August 9, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, announced it has successfully completed its multi-year collaborative agreement with Merck & Co., Inc., which utilized AVEO’s proprietary cancer models to identify and validate essential tumor maintenance

Download PDF CAMBRIDGE, MA, June 18, 2007– AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded the Ernst & Young New England Entrepreneur of the Year® in the life sciences

Download PDF Cambridge, MA – May 3, 2007 – AVEO Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced that it has closed a $53 million Series D financing.  Proceeds from this financing will be used to accelerate the development of AVEO’s pipeline of novel, clinical-stage cancer